In this context, incretin-based therapies offer a promising non-surgical approach, occupying a unique position among pharmacological agents targeting the cardio–renal–metabolic syndrome (CRMS) due to their multifaceted actions on glucose metabolism, adiposity, cardiovascular health, renal function, and systemic inflammation. Here, GCG is linked to CFTR-related metabolic syndrome/CF screen positive, inconclusive diagnosis.